Another study in 300 grades 1 and 2 meningiomas has found that 13% harbored the AKT1 p.Glu17Lys mutation [18] and displayed immunohistochemical evidence of PI3K–AKT–mTOR pathway activation. This evidence concerns the gene AKT1 and meningioma.